Literature DB >> 11702107

Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [123I]ss-CIT and high-resolution SPET.

H Barthel1, D Sorger, H J Kühn, A Wagner, R Kluge, W Hermann.   

Abstract

Wilson's disease (WD) is a copper deposition disorder which can result in a number of extrapyramidal motoric symptoms such as parkinsonism. Therefore, this study was carried out to investigate, for the first time, nigrostriatal dopaminergic function in WD in relation to different courses and severity of the disease. Using high-resolution single-photon emission tomography (SPET) after administration of 2ss-carbomethoxy-3ss-(4[123I]iodophenyl)tropane ([123I]ss-CIT), striatal dopamine transporters (DAT) were imaged in 43 WD patients and a control group of ten subjects. From the SPET images, specific [123I]ss-CIT binding ratios were obtained for the caudate heads, putamina and entire corpus striatum. In addition, to evaluate a putative dissociation between the caudate and putaminal [123I]ss-CIT binding ratios, the ratio between these binding ratios was calculated (CA/PU ratio). The SPET data were compared with clinical data on the course of the disease (CD), the severity of neurological symptoms and the degree of hepatic alteration. Whereas the specific regional [123I]ss-CIT binding ratios in patients with asymptomatic/hepatic CD did not differ from those in the control group (e.g. striatal ratios: 13.4+/-3.0 vs 11.7+/-2.8), in patients with neurological CD the ratios were significantly reduced for all striatal substructures (P=0.003 after one-factor ANOVA). For the different subgroups a tendency was detected towards a stepwise decrease in the specific [123I]ss-CIT binding ratios from pseudo-sclerosis CD (9.4+/-2.3), through pseudo-parkinsonian CD (9.1+/-2.1) to arrhythmic-hyperkinetic CD (8.5+/-1.6). However, these group differences reached significance only for the comparison with asymptomatic/hepatic CD (P=0.02). The CA/PU ratio was significantly higher in WD than in the control group (1.30+/-0.19 vs 1.11+/-0.08; P=0.003). Severity of neurological symptoms was significantly correlated with all specific regional [123I]ss-CIT binding ratios (r=-0.49 to -0.57). For degree of liver alteration, significant correlations were obtained with the putaminal binding ratio (r=-0.37) and the CA/PU ratio (r=0.44). From these results is concluded that in WD the nigrostriatal dopaminergic function is compromised to varying extents. The degree of this presynaptic alteration of dopaminergic neurotransmission depends on the clinical course and severity of this copper deposition brain disorder and also varies in the different striatal substructures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11702107     DOI: 10.1007/s002590100623

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

Review 1.  Classification and differential diagnosis of Wilson's disease.

Authors:  Wieland Hermann
Journal:  Ann Transl Med       Date:  2019-04

2.  Brain MRI, Tc-99m HMPAO SPECT and F-18 FP-CIT PET/CT Findings in a Patient with Wilson Disease: A Case Report.

Authors:  Seungyoo Kim; In Uk Song; Yong An Chung; Eun Kyung Choi; Jin Kyoung Oh
Journal:  Nucl Med Mol Imaging       Date:  2014-08-05

3.  Automated Analysis of (123)I-beta-CIT SPECT Images with Statistical Probabilistic Anatomical Mapping.

Authors:  Jae Seon Eo; Ho-Young Lee; Jae Sung Lee; Yu Kyung Kim; Bum-Seok Jeon; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2013-11-06

4.  Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms?

Authors:  K Strecker; J P Schneider; H Barthel; W Hermann; F Wegner; A Wagner; J Schwarz; O Sabri; C Zimmer
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

5.  Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease.

Authors:  Henryk Barthel; Wieland Hermann; Regine Kluge; Swen Hesse; David R Collingridge; Armin Wagner; Osama Sabri
Journal:  AJNR Am J Neuroradiol       Date:  2003-02       Impact factor: 3.825

6.  Is correction for age necessary in neuroimaging studies of the central serotonin transporter?

Authors:  Swen Hesse; Henryk Barthel; Toshiya Murai; Ulrich Müller; Dominic Müller; Anita Seese; Regine Kluge; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-16       Impact factor: 9.236

7.  ATP7A and ATP7B copper transporters have distinct functions in the regulation of neuronal dopamine-β-hydroxylase.

Authors:  Katharina Schmidt; Martina Ralle; Thomas Schaffer; Samuel Jayakanthan; Bilal Bari; Abigael Muchenditsi; Svetlana Lutsenko
Journal:  J Biol Chem       Date:  2018-10-19       Impact factor: 5.157

8.  Neurochemical and behavioral characteristics of toxic milk mice: an animal model of Wilson's disease.

Authors:  Adam Przybyłkowski; Grażyna Gromadzka; Adriana Wawer; Ewa Bulska; Katarzyna Jabłonka-Salach; Tomasz Grygorowicz; Anna Schnejder-Pachołek; Andrzej Członkowski
Journal:  Neurochem Res       Date:  2013-07-23       Impact factor: 3.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.